Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary) ; Hib vaccine conjugate (Primary) ; Hib-DTaP-poliovirus vaccine (Primary) ; Measles mumps and rubella virus vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Rotavirus W179-9 vaccine (Primary) ; V 114 (Primary) ; Varicella zoster virus vaccine live (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms PNEU-DIRECTION
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 Dec 2022 Results evaluating safety and immunogenicity of mixed PCV13/V114 regimens, published in the Vaccine
    • 22 Jun 2022 According to a Merck & Co media release, the U.S. Food and Drug Administration (FDA) has approved an expanded indication for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) to include children 6 weeks through 17 years of age. The approval follows the FDA's Priority Review of Merck's supplemental application. This approval based on data from seven trials including NCT03893448, NCT03620162, NCT03885934.
    • 20 May 2021 According to a media release, full results from PNEU-DIRECTION will be presented at a future scientific congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top